Associations of Oral Contraceptive Use With Cardiovascular Disease and All‐Cause Death: Evidence From the UK Biobank Cohort Study

Background The associations of oral contraceptive (OC) use with cardiovascular disease (CVD) and all-cause death remains unclear. We aimed to determine the associations of OC use with incident CVD and all-cause death. Methods and Results This cohort study included 161 017 women who had no CVD at bas...

Full description

Saved in:
Bibliographic Details
Published inJournal of the American Heart Association Vol. 12; no. 16; p. e030105
Main Authors Dou, Weijuan, Huang, Yan, Liu, Xuesong, Huang, Chensihan, Huang, Junlin, Xu, Bingyan, Yang, Linjie, Liu, Yating, Lei, Xuzhen, Li, Xu, Huang, Junfeng, Lin, Jiayang, Liu, Deying, Zhang, Peizhen, Shao, Jiaqing, Liu, Changqin, Zhang, Huijie
Format Journal Article
LanguageEnglish
Published England John Wiley and Sons Inc 15.08.2023
Wiley
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Background The associations of oral contraceptive (OC) use with cardiovascular disease (CVD) and all-cause death remains unclear. We aimed to determine the associations of OC use with incident CVD and all-cause death. Methods and Results This cohort study included 161 017 women who had no CVD at baseline and reported their OC use. We divided OC use into ever use and never use. Cox proportional hazard models were used to calculate hazard ratios and 95% CIs for cardiovascular outcomes and death. Overall, 131 131 (81.4%) of 161 017 participants reported OC use at baseline. The multivariable-adjusted hazard ratios for OC ever users versus never users were 0.92 (95% CI, 0.86-0.99) for all-cause death, 0.91 (95% CI, 0.87-0.96) for incident CVD events, 0.88 (95% CI, 0.81-0.95) for coronary heart disease, 0.87 (95% CI, 0.76-0.99) for heart failure, and 0.92 (95% CI, 0.84-0.99) for atrial fibrillation. However, no significant associations of OC use with CVD death, myocardial infarction, or stroke were observed. Furthermore, the associations of OC use with CVD events were stronger among participants with longer durations of use ( for trend<0.001). Conclusions OC use was not associated with an increased risk of CVD events and all-cause death in women and may even produce an apparent net benefit. In addition, the beneficial effects appeared to be more apparent in participants with longer durations of use.
AbstractList Background The associations of oral contraceptive (OC) use with cardiovascular disease (CVD) and all‐cause death remains unclear. We aimed to determine the associations of OC use with incident CVD and all‐cause death. Methods and Results This cohort study included 161 017 women who had no CVD at baseline and reported their OC use. We divided OC use into ever use and never use. Cox proportional hazard models were used to calculate hazard ratios and 95% CIs for cardiovascular outcomes and death. Overall, 131 131 (81.4%) of 161 017 participants reported OC use at baseline. The multivariable‐adjusted hazard ratios for OC ever users versus never users were 0.92 (95% CI, 0.86–0.99) for all‐cause death, 0.91 (95% CI, 0.87–0.96) for incident CVD events, 0.88 (95% CI, 0.81–0.95) for coronary heart disease, 0.87 (95% CI, 0.76–0.99) for heart failure, and 0.92 (95% CI, 0.84–0.99) for atrial fibrillation. However, no significant associations of OC use with CVD death, myocardial infarction, or stroke were observed. Furthermore, the associations of OC use with CVD events were stronger among participants with longer durations of use (P for trend<0.001). Conclusions OC use was not associated with an increased risk of CVD events and all‐cause death in women and may even produce an apparent net benefit. In addition, the beneficial effects appeared to be more apparent in participants with longer durations of use.
Background The associations of oral contraceptive (OC) use with cardiovascular disease (CVD) and all-cause death remains unclear. We aimed to determine the associations of OC use with incident CVD and all-cause death. Methods and Results This cohort study included 161 017 women who had no CVD at baseline and reported their OC use. We divided OC use into ever use and never use. Cox proportional hazard models were used to calculate hazard ratios and 95% CIs for cardiovascular outcomes and death. Overall, 131 131 (81.4%) of 161 017 participants reported OC use at baseline. The multivariable-adjusted hazard ratios for OC ever users versus never users were 0.92 (95% CI, 0.86-0.99) for all-cause death, 0.91 (95% CI, 0.87-0.96) for incident CVD events, 0.88 (95% CI, 0.81-0.95) for coronary heart disease, 0.87 (95% CI, 0.76-0.99) for heart failure, and 0.92 (95% CI, 0.84-0.99) for atrial fibrillation. However, no significant associations of OC use with CVD death, myocardial infarction, or stroke were observed. Furthermore, the associations of OC use with CVD events were stronger among participants with longer durations of use ( for trend<0.001). Conclusions OC use was not associated with an increased risk of CVD events and all-cause death in women and may even produce an apparent net benefit. In addition, the beneficial effects appeared to be more apparent in participants with longer durations of use.
Background The associations of oral contraceptive (OC) use with cardiovascular disease (CVD) and all-cause death remains unclear. We aimed to determine the associations of OC use with incident CVD and all-cause death. Methods and Results This cohort study included 161 017 women who had no CVD at baseline and reported their OC use. We divided OC use into ever use and never use. Cox proportional hazard models were used to calculate hazard ratios and 95% CIs for cardiovascular outcomes and death. Overall, 131 131 (81.4%) of 161 017 participants reported OC use at baseline. The multivariable-adjusted hazard ratios for OC ever users versus never users were 0.92 (95% CI, 0.86-0.99) for all-cause death, 0.91 (95% CI, 0.87-0.96) for incident CVD events, 0.88 (95% CI, 0.81-0.95) for coronary heart disease, 0.87 (95% CI, 0.76-0.99) for heart failure, and 0.92 (95% CI, 0.84-0.99) for atrial fibrillation. However, no significant associations of OC use with CVD death, myocardial infarction, or stroke were observed. Furthermore, the associations of OC use with CVD events were stronger among participants with longer durations of use (P for trend<0.001). Conclusions OC use was not associated with an increased risk of CVD events and all-cause death in women and may even produce an apparent net benefit. In addition, the beneficial effects appeared to be more apparent in participants with longer durations of use.Background The associations of oral contraceptive (OC) use with cardiovascular disease (CVD) and all-cause death remains unclear. We aimed to determine the associations of OC use with incident CVD and all-cause death. Methods and Results This cohort study included 161 017 women who had no CVD at baseline and reported their OC use. We divided OC use into ever use and never use. Cox proportional hazard models were used to calculate hazard ratios and 95% CIs for cardiovascular outcomes and death. Overall, 131 131 (81.4%) of 161 017 participants reported OC use at baseline. The multivariable-adjusted hazard ratios for OC ever users versus never users were 0.92 (95% CI, 0.86-0.99) for all-cause death, 0.91 (95% CI, 0.87-0.96) for incident CVD events, 0.88 (95% CI, 0.81-0.95) for coronary heart disease, 0.87 (95% CI, 0.76-0.99) for heart failure, and 0.92 (95% CI, 0.84-0.99) for atrial fibrillation. However, no significant associations of OC use with CVD death, myocardial infarction, or stroke were observed. Furthermore, the associations of OC use with CVD events were stronger among participants with longer durations of use (P for trend<0.001). Conclusions OC use was not associated with an increased risk of CVD events and all-cause death in women and may even produce an apparent net benefit. In addition, the beneficial effects appeared to be more apparent in participants with longer durations of use.
Author Huang, Junlin
Liu, Deying
Yang, Linjie
Li, Xu
Zhang, Peizhen
Huang, Junfeng
Liu, Xuesong
Lei, Xuzhen
Huang, Yan
Xu, Bingyan
Shao, Jiaqing
Liu, Yating
Dou, Weijuan
Lin, Jiayang
Liu, Changqin
Huang, Chensihan
Zhang, Huijie
AuthorAffiliation 1 Department of Endocrinology and Metabolism, Nanfang Hospital Southern Medical University Guangzhou China
4 State Key Laboratory of Organ Failure Research, National Clinical Research Center for Kidney Disease Nanfang Hospital, Southern Medical University Guangzhou China
5 Department of Food Safety and Health Research Center, School of Public Health Southern Medical University Guangzhou Guangdong China
7 Department of Endocrinology and Metabolism The First Affiliated Hospital of Xiamen University Xiamen China
2 Department of Endocrinology, Jinling Hospital Medical School of Nanjing University Nanjing China
3 Guangdong Provincial Key Laboratory of Cardiac Function and Microcirculation Guangzhou China
6 State Key Lab of Respiratory Diseases, Guangzhou Institute of Respiratory Health, Department of Critical Care Medicine The First Affiliated Hospital of Guangzhou Medical University Guangzhou China
AuthorAffiliation_xml – name: 5 Department of Food Safety and Health Research Center, School of Public Health Southern Medical University Guangzhou Guangdong China
– name: 1 Department of Endocrinology and Metabolism, Nanfang Hospital Southern Medical University Guangzhou China
– name: 6 State Key Lab of Respiratory Diseases, Guangzhou Institute of Respiratory Health, Department of Critical Care Medicine The First Affiliated Hospital of Guangzhou Medical University Guangzhou China
– name: 2 Department of Endocrinology, Jinling Hospital Medical School of Nanjing University Nanjing China
– name: 3 Guangdong Provincial Key Laboratory of Cardiac Function and Microcirculation Guangzhou China
– name: 4 State Key Laboratory of Organ Failure Research, National Clinical Research Center for Kidney Disease Nanfang Hospital, Southern Medical University Guangzhou China
– name: 7 Department of Endocrinology and Metabolism The First Affiliated Hospital of Xiamen University Xiamen China
Author_xml – sequence: 1
  givenname: Weijuan
  orcidid: 0000-0002-3754-1068
  surname: Dou
  fullname: Dou, Weijuan
  organization: Department of Endocrinology and Metabolism, Nanfang Hospital Southern Medical University Guangzhou China, Department of Endocrinology, Jinling Hospital Medical School of Nanjing University Nanjing China, Guangdong Provincial Key Laboratory of Cardiac Function and Microcirculation Guangzhou China, State Key Laboratory of Organ Failure Research, National Clinical Research Center for Kidney Disease Nanfang Hospital, Southern Medical University Guangzhou China
– sequence: 2
  givenname: Yan
  surname: Huang
  fullname: Huang, Yan
  organization: Department of Endocrinology and Metabolism, Nanfang Hospital Southern Medical University Guangzhou China, Guangdong Provincial Key Laboratory of Cardiac Function and Microcirculation Guangzhou China, State Key Laboratory of Organ Failure Research, National Clinical Research Center for Kidney Disease Nanfang Hospital, Southern Medical University Guangzhou China, Department of Food Safety and Health Research Center, School of Public Health Southern Medical University Guangzhou Guangdong China
– sequence: 3
  givenname: Xuesong
  surname: Liu
  fullname: Liu, Xuesong
  organization: State Key Lab of Respiratory Diseases, Guangzhou Institute of Respiratory Health, Department of Critical Care Medicine The First Affiliated Hospital of Guangzhou Medical University Guangzhou China
– sequence: 4
  givenname: Chensihan
  surname: Huang
  fullname: Huang, Chensihan
  organization: Department of Endocrinology and Metabolism, Nanfang Hospital Southern Medical University Guangzhou China
– sequence: 5
  givenname: Junlin
  surname: Huang
  fullname: Huang, Junlin
  organization: Department of Endocrinology and Metabolism, Nanfang Hospital Southern Medical University Guangzhou China
– sequence: 6
  givenname: Bingyan
  orcidid: 0000-0002-9162-5692
  surname: Xu
  fullname: Xu, Bingyan
  organization: Department of Endocrinology and Metabolism, Nanfang Hospital Southern Medical University Guangzhou China
– sequence: 7
  givenname: Linjie
  surname: Yang
  fullname: Yang, Linjie
  organization: Department of Endocrinology and Metabolism, Nanfang Hospital Southern Medical University Guangzhou China
– sequence: 8
  givenname: Yating
  surname: Liu
  fullname: Liu, Yating
  organization: Department of Endocrinology and Metabolism, Nanfang Hospital Southern Medical University Guangzhou China
– sequence: 9
  givenname: Xuzhen
  orcidid: 0000-0001-8007-5296
  surname: Lei
  fullname: Lei, Xuzhen
  organization: Department of Endocrinology and Metabolism, Nanfang Hospital Southern Medical University Guangzhou China
– sequence: 10
  givenname: Xu
  surname: Li
  fullname: Li, Xu
  organization: Department of Endocrinology and Metabolism, Nanfang Hospital Southern Medical University Guangzhou China
– sequence: 11
  givenname: Junfeng
  orcidid: 0009-0008-4308-8846
  surname: Huang
  fullname: Huang, Junfeng
  organization: Department of Endocrinology and Metabolism, Nanfang Hospital Southern Medical University Guangzhou China
– sequence: 12
  givenname: Jiayang
  orcidid: 0000-0001-9887-976X
  surname: Lin
  fullname: Lin, Jiayang
  organization: Department of Endocrinology and Metabolism, Nanfang Hospital Southern Medical University Guangzhou China
– sequence: 13
  givenname: Deying
  surname: Liu
  fullname: Liu, Deying
  organization: Department of Endocrinology and Metabolism, Nanfang Hospital Southern Medical University Guangzhou China
– sequence: 14
  givenname: Peizhen
  surname: Zhang
  fullname: Zhang, Peizhen
  organization: Department of Endocrinology and Metabolism, Nanfang Hospital Southern Medical University Guangzhou China
– sequence: 15
  givenname: Jiaqing
  surname: Shao
  fullname: Shao, Jiaqing
  organization: Department of Endocrinology, Jinling Hospital Medical School of Nanjing University Nanjing China
– sequence: 16
  givenname: Changqin
  surname: Liu
  fullname: Liu, Changqin
  organization: Department of Endocrinology and Metabolism The First Affiliated Hospital of Xiamen University Xiamen China
– sequence: 17
  givenname: Huijie
  orcidid: 0000-0003-0640-0315
  surname: Zhang
  fullname: Zhang, Huijie
  organization: Department of Endocrinology and Metabolism, Nanfang Hospital Southern Medical University Guangzhou China, Guangdong Provincial Key Laboratory of Cardiac Function and Microcirculation Guangzhou China, State Key Laboratory of Organ Failure Research, National Clinical Research Center for Kidney Disease Nanfang Hospital, Southern Medical University Guangzhou China, Department of Food Safety and Health Research Center, School of Public Health Southern Medical University Guangzhou Guangdong China
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37581386$$D View this record in MEDLINE/PubMed
BookMark eNp1ks9u1DAQxiNUREvpmRvykctu7dhJHC5oSVtaqNQDVBytiT1pXLLx1nZW6g2JF-AZeRK83VK1SPhij-eb3_jP9zLbGd2IWfaa0TljJTv8tDhdzFnO55RTRotn2V5ORTWra0l3Hq13s4MQrmkaZV7xon6R7fKqkIzLci_7uQjBaQvRujEQ15ELDwNp3Bg9aFxFu0ZyGZB8s7EnDXhj3RqCngbw5MgGhJSD0ZDFMPz-8auBKcVHCLF_R47X1uCokZx4tySxT6DP5IN1LYzfU4fe-Ui-xMncvsqedzAEPLif97PLk-Ovzens_OLjWbM4n2lR0jgzmlLTGZOzVgCvIF2NIQOGvANaYllKYTRjCFq0XaW55lKXUkojJdMyL_h-drblGgfXauXtEvytcmDV3YbzVwp8tHpAhaYyphO8pB0XtS5kS9u6Y1p0lBlhWGK937JWU7tEo3HzYMMT6NPMaHt15daKUVHntcgT4e09wbubCUNUSxs0DgOM6KagclkwJnhBeZK-edzsocvfb0yCw61AexeCx-5BwqjaeEVtvKKSV9TWK6mi-KdC23jngnRaO_y37g9AwMRC
CitedBy_id crossref_primary_10_1016_j_steroids_2024_109423
crossref_primary_10_3390_ijtm4040052
crossref_primary_10_1016_j_contraception_2025_110861
crossref_primary_10_26599_1671_5411_2024_06_003
crossref_primary_10_1016_j_artere_2024_02_002
crossref_primary_10_1016_j_arteri_2023_10_001
crossref_primary_10_1097_MED_0000000000000882
crossref_primary_10_1210_clinem_dgae655
crossref_primary_10_1139_cjpp_2024_0041
crossref_primary_10_1186_s12982_024_00166_1
crossref_primary_10_1007_s11897_024_00657_x
crossref_primary_10_1007_s12609_024_00534_5
crossref_primary_10_61622_rbgo_2024rbgo100
crossref_primary_10_1016_S1889_1837_24_00075_8
Cites_doi 10.1136/bmj.318.7198.1579
10.1016/j.fertnstert.2004.07.135
10.1016/0002-9378(90)91353-E
10.1136/jim-2018-000750
10.1371/journal.pmed.1001779
10.1016/j.bpobgyn.2014.06.003
10.1210/jcem.87.5.8471
10.1161/01.ATV.15.12.2094
10.1136/bmj.i2002
10.1016/S0140-6736(97)02358-1
10.1093/aje/kwu224
10.1016/S0735-1097(02)02763-8
10.1016/S0140-6736(12)60404-8
10.1016/j.fertnstert.2006.01.009
10.1016/j.contraception.2003.08.014
10.1056/NEJMoa1111840
10.1002/14651858.CD011054.pub2
10.1210/jcem.80.6.7775629
10.1016/j.pharmthera.2012.03.007
10.1089/jwh.2020.8743
10.1056/NEJM199906103402306
10.1016/j.fertnstert.2006.11.206
10.1056/NEJMoa003216
10.1016/S0010-7824(00)00149-9
10.1097/AOG.0b013e3182994c43
10.1136/bmj-2022-072157
10.1016/j.jacc.2008.09.042
10.1210/jc.2007-2025
10.1136/bmj.g6356
10.1016/S0140-6736(12)60478-4
10.1136/bmj.k4247
10.1016/j.contraception.2010.04.006
10.1136/bmj.b2393
10.1016/S0022-2275(20)30144-9
10.1080/14034940510032239
10.1016/j.contraception.2007.01.027
10.1056/NEJM198811173192004
10.1158/0008-5472.CAN-20-2476
10.1093/oxfordjournals.eurheartj.a061365
10.1016/s0029-7844(00)00891-7
10.1136/bmj.c927
10.1002/ehf2.13328
10.3275/8882
ContentType Journal Article
Copyright 2023 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.
Copyright_xml – notice: 2023 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.
DBID AAYXX
CITATION
NPM
7X8
5PM
DOA
DOI 10.1161/JAHA.123.030105
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList
PubMed
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate Association of OC Use With CVD
EISSN 2047-9980
ExternalDocumentID oai_doaj_org_article_ed7ddf4360f349c58b0b9f1c4f01d4d1
PMC10492942
37581386
10_1161_JAHA_123_030105
Genre Journal Article
GrantInformation_xml – fundername: Key‐Area Clinical Research Program of Southern Medical University
  grantid: LC2019ZD010
– fundername: 2019CR022
– fundername: National Key Research and Development Project
  grantid: 2018YFA0800404
– fundername: ;
  grantid: U22A20288; 81970736
GroupedDBID 0R~
1OC
24P
53G
5VS
8-1
AAYXX
AAZKR
ACCMX
ACGFO
ACXQS
ADBBV
ADKYN
ADZMN
AEGXH
AENEX
AIAGR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AVUZU
BAWUL
BCNDV
CITATION
DIK
EBS
EMOBN
GODZA
GROUPED_DOAJ
GX1
HYE
KQ8
M48
M~E
OK1
RAH
RNS
RPM
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
NPM
7X8
5PM
WIN
ID FETCH-LOGICAL-c460t-dc00dfdd21b4a37a9801e1a1e3fa06e6684dc11eac4bf7c3c38c6888d881c8253
IEDL.DBID M48
ISSN 2047-9980
IngestDate Wed Aug 27 01:32:00 EDT 2025
Thu Aug 21 18:36:24 EDT 2025
Thu Jul 10 23:48:51 EDT 2025
Mon Jul 21 05:55:14 EDT 2025
Tue Jul 01 03:15:35 EDT 2025
Thu Apr 24 22:52:38 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 16
Keywords cardiovascular disease
oral contraceptive use
all‐cause death
women's health
Language English
License This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c460t-dc00dfdd21b4a37a9801e1a1e3fa06e6684dc11eac4bf7c3c38c6888d881c8253
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
For Sources of Funding and Disclosures, see page 9.
W. Dou, Y. Huang, and X. Liu contributed equally.
This manuscript was sent to Mahasin S. Mujahid, PhD, MS, FAHA, Associate Editor, for review by expert referees, editorial decision, and final disposition.
Supplemental Material is available at https://www.ahajournals.org/doi/suppl/10.1161/JAHA.123.030105
ORCID 0000-0002-9162-5692
0000-0003-0640-0315
0000-0001-9887-976X
0009-0008-4308-8846
0000-0001-8007-5296
0000-0002-3754-1068
OpenAccessLink https://doaj.org/article/ed7ddf4360f349c58b0b9f1c4f01d4d1
PMID 37581386
PQID 2851143503
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_ed7ddf4360f349c58b0b9f1c4f01d4d1
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10492942
proquest_miscellaneous_2851143503
pubmed_primary_37581386
crossref_primary_10_1161_JAHA_123_030105
crossref_citationtrail_10_1161_JAHA_123_030105
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-08-15
PublicationDateYYYYMMDD 2023-08-15
PublicationDate_xml – month: 08
  year: 2023
  text: 2023-08-15
  day: 15
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: Hoboken
PublicationTitle Journal of the American Heart Association
PublicationTitleAlternate J Am Heart Assoc
PublicationYear 2023
Publisher John Wiley and Sons Inc
Wiley
Publisher_xml – name: John Wiley and Sons Inc
– name: Wiley
References e_1_3_2_26_2
e_1_3_2_27_2
e_1_3_2_28_2
e_1_3_2_29_2
e_1_3_2_41_2
e_1_3_2_40_2
e_1_3_2_20_2
e_1_3_2_43_2
e_1_3_2_21_2
e_1_3_2_42_2
e_1_3_2_22_2
e_1_3_2_23_2
e_1_3_2_44_2
e_1_3_2_24_2
e_1_3_2_25_2
e_1_3_2_9_2
e_1_3_2_15_2
e_1_3_2_38_2
e_1_3_2_8_2
e_1_3_2_16_2
e_1_3_2_37_2
e_1_3_2_7_2
e_1_3_2_17_2
e_1_3_2_6_2
e_1_3_2_18_2
e_1_3_2_39_2
e_1_3_2_19_2
e_1_3_2_30_2
e_1_3_2_32_2
e_1_3_2_10_2
e_1_3_2_31_2
e_1_3_2_5_2
e_1_3_2_11_2
e_1_3_2_34_2
e_1_3_2_4_2
e_1_3_2_12_2
e_1_3_2_33_2
e_1_3_2_3_2
e_1_3_2_13_2
e_1_3_2_36_2
e_1_3_2_2_2
e_1_3_2_14_2
e_1_3_2_35_2
References_xml – ident: e_1_3_2_3_2
  doi: 10.1136/bmj.318.7198.1579
– ident: e_1_3_2_17_2
  doi: 10.1016/j.fertnstert.2004.07.135
– ident: e_1_3_2_14_2
  doi: 10.1016/0002-9378(90)91353-E
– ident: e_1_3_2_9_2
  doi: 10.1136/jim-2018-000750
– ident: e_1_3_2_20_2
  doi: 10.1371/journal.pmed.1001779
– ident: e_1_3_2_39_2
  doi: 10.1016/j.bpobgyn.2014.06.003
– ident: e_1_3_2_42_2
  doi: 10.1210/jcem.87.5.8471
– ident: e_1_3_2_15_2
  doi: 10.1161/01.ATV.15.12.2094
– ident: e_1_3_2_26_2
  doi: 10.1136/bmj.i2002
– ident: e_1_3_2_8_2
  doi: 10.1016/S0140-6736(97)02358-1
– ident: e_1_3_2_24_2
  doi: 10.1093/aje/kwu224
– ident: e_1_3_2_41_2
  doi: 10.1016/S0735-1097(02)02763-8
– ident: e_1_3_2_21_2
  doi: 10.1016/S0140-6736(12)60404-8
– ident: e_1_3_2_30_2
  doi: 10.1016/j.fertnstert.2006.01.009
– ident: e_1_3_2_35_2
  doi: 10.1016/j.contraception.2003.08.014
– ident: e_1_3_2_2_2
  doi: 10.1056/NEJMoa1111840
– ident: e_1_3_2_7_2
  doi: 10.1002/14651858.CD011054.pub2
– ident: e_1_3_2_36_2
  doi: 10.1210/jcem.80.6.7775629
– ident: e_1_3_2_37_2
  doi: 10.1016/j.pharmthera.2012.03.007
– ident: e_1_3_2_12_2
  doi: 10.1089/jwh.2020.8743
– ident: e_1_3_2_13_2
  doi: 10.1056/NEJM199906103402306
– ident: e_1_3_2_29_2
  doi: 10.1016/j.fertnstert.2006.11.206
– ident: e_1_3_2_18_2
  doi: 10.1056/NEJMoa003216
– ident: e_1_3_2_19_2
  doi: 10.1016/S0010-7824(00)00149-9
– ident: e_1_3_2_40_2
  doi: 10.1097/AOG.0b013e3182994c43
– ident: e_1_3_2_23_2
  doi: 10.1136/bmj-2022-072157
– ident: e_1_3_2_32_2
  doi: 10.1016/j.jacc.2008.09.042
– ident: e_1_3_2_43_2
  doi: 10.1210/jc.2007-2025
– ident: e_1_3_2_6_2
  doi: 10.1136/bmj.g6356
– ident: e_1_3_2_44_2
  doi: 10.1016/S0140-6736(12)60478-4
– ident: e_1_3_2_22_2
  doi: 10.1136/bmj.k4247
– ident: e_1_3_2_28_2
  doi: 10.1016/j.contraception.2010.04.006
– ident: e_1_3_2_25_2
  doi: 10.1136/bmj.b2393
– ident: e_1_3_2_33_2
  doi: 10.1016/S0022-2275(20)30144-9
– ident: e_1_3_2_11_2
  doi: 10.1080/14034940510032239
– ident: e_1_3_2_34_2
  doi: 10.1016/j.contraception.2007.01.027
– ident: e_1_3_2_10_2
  doi: 10.1056/NEJM198811173192004
– ident: e_1_3_2_5_2
  doi: 10.1158/0008-5472.CAN-20-2476
– ident: e_1_3_2_16_2
  doi: 10.1093/oxfordjournals.eurheartj.a061365
– ident: e_1_3_2_38_2
  doi: 10.1016/s0029-7844(00)00891-7
– ident: e_1_3_2_27_2
  doi: 10.1136/bmj.c927
– ident: e_1_3_2_31_2
  doi: 10.1002/ehf2.13328
– ident: e_1_3_2_4_2
  doi: 10.3275/8882
SSID ssj0000627359
Score 2.4228919
Snippet Background The associations of oral contraceptive (OC) use with cardiovascular disease (CVD) and all-cause death remains unclear. We aimed to determine the...
Background The associations of oral contraceptive (OC) use with cardiovascular disease (CVD) and all‐cause death remains unclear. We aimed to determine the...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage e030105
SubjectTerms all‐cause death
cardiovascular disease
oral contraceptive use
Original Research
women's health
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3LbtQwFLVQFxUbBC2FAEWu1AWbtHbsOA676ZTRqFVhw6jdWX5qRgwZNI9K3SHxA3wjX9LrJDPKoKJuWOZt-V77nmPfnIvQMfgJkASdpTYnNpYw06mxksK4KoJnWmrC4__OV5_FcMQvbvKbTqmvmBPWyAM3HXfqXeFc4EyQwHhpc2mIKQO1PBDquKuJD8S8Dplq5mAIy3nZavkAqjm96A3jwh87iRwgFqvrhKFarf8hiPl3pmQn9Ayeo2ctZsS9pq0v0BNf7aHdq3ZXfB_96vTxAs8C_gIvwVF3aq7rrJVbj0cLj68nyzHubyWg4vNmgwbryuHedPrn5---XsHxeYSGH_G66CgezGffMYBFPLrEZxOYBKpv8IUxgHccUxHvXqLR4NPX_jBtiyuklguyTJ0lxAXnMmq4ZoUuIVR5qqlnQRPhhZDcWUphXuYmFJZZJq0AuuykpBZoJTtAO9Ws8q8Rli4Qrxl1GTfcs9JkEswMqF0bWhaMJ-hk3dfKtsrjsQDGVNUMRFAVjaPAOKoxToI-bB740Yhu_PvWs2i8zW1RLbs-AT6kWh9Sj_lQgo7WplcwuuKWia78bLVQWQSkgCgJS9CrxhU2n2JAtSiTIkFyy0m22rJ9pZqMawVv4MAAS3n25n-0_i16mgHyigvdNH-HdpbzlT8EpLQ07-tBcQ9h2RLY
  priority: 102
  providerName: Directory of Open Access Journals
Title Associations of Oral Contraceptive Use With Cardiovascular Disease and All‐Cause Death: Evidence From the UK Biobank Cohort Study
URI https://www.ncbi.nlm.nih.gov/pubmed/37581386
https://www.proquest.com/docview/2851143503
https://pubmed.ncbi.nlm.nih.gov/PMC10492942
https://doaj.org/article/ed7ddf4360f349c58b0b9f1c4f01d4d1
Volume 12
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lj9MwELbQIiEuiDfhsTISBy4pduw6LhJC3S5VtahwIWJvluPHtqIkkLaIPfLPGTtp2aAicUzi2NE87G_syTcIvQA7gSBBZ6kZEhNKmOm0NJKCX-XeMS014eF_5_kHMSv42fnw_E85oE6A64OhXagnVTSrwc_vl2_B4d9Ehxf01dl4Fvb02CDA-8Bneh2WpTx46bzD-u20DCt1LJ6WBXYCCDNIR_VzoI_eKhXJ_A8h0L8TKa-sTNPb6FYHKfG4tYE76Jqr7qIb8-7Q_B76dUUFa1x7_BE6wYGWqtExqeWHw8Xa4c_LzQJPevmp-LQ9v8G6sni8WqUTvYWr04AbX-NdRVI8beqvGJAkLt7jkyXMENUX6H8BQsUhT_HyPiqm7z5NZmlXeSE1XJBNag0h1lub0ZJrlmuQFXVUU8e8JsIJIbk1lMKkzUufG2aYNAJiaSslNRBzsgfoqKor9whhaT1xmlGb8ZI7NiozCTYAkF6XdJQznqDBTtLKdLTkoTrGSsXwRFAVVKNANapVTYJe7l_41jJy_LvpSVDdvlmg0o436uZCdZ6pnM2t9ZwJ4hkfmaEsSTny1HBPqOWWJuj5TvEKXC-cp-jK1du1ygJaBbhJWIIetoawH4pBHEaZFAmSPRPpfUv_SbVcRHpvCJABs_Ls8X8M_ATdzAB1hU1uOnyKjjbN1j0DlLQpj-PuwnH0gd9Weg8e
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Associations+of+Oral+Contraceptive+Use+With+Cardiovascular+Disease+and+All-Cause+Death%3A+Evidence+From+the+UK+Biobank+Cohort+Study&rft.jtitle=Journal+of+the+American+Heart+Association&rft.au=Dou%2C+Weijuan&rft.au=Huang%2C+Yan&rft.au=Liu%2C+Xuesong&rft.au=Huang%2C+Chensihan&rft.date=2023-08-15&rft.issn=2047-9980&rft.eissn=2047-9980&rft.volume=12&rft.issue=16&rft.spage=e030105&rft_id=info:doi/10.1161%2FJAHA.123.030105&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2047-9980&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2047-9980&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2047-9980&client=summon